Lupin Overview
Company Headquarter: Mumbai, India
Founded: 1968
Workforce: 15,000+
Company Working:
Lupin is a global pharmaceutical company that deals in a wide range of products such as branded and generic formulations, biotechnology products, APIs, and specialty drugs. The company is a prominent player in the therapeutic segment such as gynecology, cardiovascular, diabetology, asthma, pediatric, central nervous system, gastrointestinal (GI), anti-infective (AI), and non-steroidal anti-inflammatory drugs (NSAIDS). Also, it has a global leader in the fields of the anti-TB and Cephalosporin segment. Lupin has a presence in more than 100 countries. It has 18 manufacturing facilities, located in many parts of India, Japan, the US, Mexico, and Brazil. All these facilities are benchmarked to international standards to meet stringent quality standards. Also, these facilities are approved by international agencies such as the US FDA, UK MHRA, Japan’s MHLW, TGA Australia, WHO, and the MCC South Africa.
Strategy
Lupin improves its clinical outcomes through new, more accurate, and fast, innovative methods. It focusses on optimizing the cost of capital based on market conditions and makes investments in untapped markets. The company wants to build an efficient capital structure and strong shareholder returns by enhancing its disease management programs in active pharmaceutical ingredients and others.
